Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 3/2020

01-05-2020 | Glioma | Clinical Study

Adult primary high-grade spinal glioma: a nationwide analysis of current trends in treatment and outcomes

Authors: Ravi S. Nunna, Syed Khalid, James S. Ryoo, Ankit I. Mehta

Published in: Journal of Neuro-Oncology | Issue 3/2020

Login to get access

Abstract

Purpose

High-grade spinal glioma (HGSG) is an extremely rare, malignant neoplasm insufficiently described in the literature. We sought to investigate the effect of epidemiological risk factors and treatment strategies on the prognosis of HGSGs using the National Cancer Database (NCDB).

Methods

Patients with diagnosis codes specific for HGSG were queried from the NCDB during the years 2004–2016. Kaplan–Meier curves were generated with log-rank testing performed to assess factors affecting survival. Univariate and multivariate Cox regression analysis was also performed to investigate overall survival.

Results

396 patients were identified with a histologically-confirmed diagnosis of HGSG between 2004–2016. The mean survival time for all patients was 24.5 months (SD: 20.3). Multivariate Cox proportional-hazards regression analysis revealed that tumor size of 26–50 mm (HR 4.96, 95% CI 1.76–13.98, p < 0.01) and greater than 50 mm (HR 4.67, 95% CI 1.43–15.23, p = 0.01) were associated with worsened overall survival in comparison to lesions less than 26 mm. While quality of life was not investigated, both Kaplan–Meier log-rank testing and regression analysis failed to demonstrate an association of survival outcomes with extent of resection, radiotherapy, or chemotherapy.

Conclusion

The current study represents the largest retrospective analysis of adult primary high-grade spinal glioma to date. Our analysis found no relationship between the extent of surgical resection and survival outcomes. In addition, we failed to show any statistically significant survival benefit with radiotherapy or chemotherapy. This disease process has a poor prognosis without a current modality of treatment that improves survival.
Literature
1.
Chamberlain MC, Tredway TL (2011) Adult primary in- tradural spinal cord tumors: a review. Curr Neurol Neurosci Rep 11:320–328CrossRef
2.
Epstein FJ, Farmer JP, Freed D (1992) Adult intramedullary astrocytomas of the spinal cord. J Neurosurg 77:355–359CrossRef
3.
Minehan KJ, Shaw EG, Scheithauer BW, Davis DL, Onofrio BM (1995) Spinal cord astrocytoma: pathological and treatment considerations. J Neurosurg 83:590–595CrossRef
4.
Wong AP, Dahdaleh NS, Fessler RG et al (2013) Risk factors and long-term survival in adult patients with primary malignant spinal cord astrocytomas. J Neurooncol 115:493–503CrossRef
5.
Seki T, Hida K, Yano S et al (2015) Surgical outcomes of high- grade spinal cord gliomas. Asian Spine J 9:935–941CrossRef
6.
Choi SH, Yoon HI, Yi S et al (2019) Treatment outcomes of radiotherapy for primary spinal cord glioma. Strahlenther Onkol 195(2):164–174CrossRef
7.
Ryu SJ, Kim JY, Kim KH et al (2016) A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation. Eur Spine J 25(12):4067–4079CrossRef
8.
Raco A, Piccirilli M, Landi A, Lenzi J, Delfini R, Cantore G (2010) High-grade intramedullary astrocytomas: 30 years’ experience at the neurosurgery department of the University of Rome “Sapienza”. J Neurosurg Spine 12(2):144–153CrossRef
9.
McGirt MJ, Goldstein IM, Chaichana KL, Tobias ME, Kothbauer KF, Jallo GI (2008) Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients. Neurosurgery 63(1):55–61CrossRef
10.
Babu R, Karikari IO, Owens TR, Bagley CA (2014) Spinal cord astrocytomas: a modern 20-year experience at a single institution. Spine 39(7):533–540CrossRef
11.
Minehan KJ, Brown PD, Scheithauer BW, Krauss WE, Wright MP (2009) Prognosis and treatment of spinal cord astrocytoma. Int J Radiat Oncol Biol Phys 73(3):727–733CrossRef
12.
Nakamura M, Chiba K, Ishii K et al (2006) Surgical outcomes of spinal cord astrocytomas. Spinal Cord 44(12):740–745CrossRef
13.
Hamilton KR, Lee SS, Urquhart JC, Jonker BP (2019) A systematic review of outcome in intramedullary ependymoma and astrocytoma. J Clin Neurosci 63:168–175CrossRef
14.
Kahn J, Loeffler JS, Niemierko A, Chiocca EA, Batchelor T, Chakravarti A (2011) Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. Int J Radiat Oncol Biol Phys 81(1):232–238CrossRef
15.
Lee SH, Chung CK, Kim CH et al (2013) Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group. Neuro-Oncology 15(7):921–929CrossRef
16.
Lin YH, Huang CI, Wong TT et al (2005) Treatment of spinal cord ependymomas by surgery with or without postoperative radiotherapy. J Neurooncol 71(2):205–210CrossRef
17.
Wahab SH, Simpson JR, Michalski JM, Mansur DB (2007) Long term outcome with post-operative radiation therapy for spinal canal ependymoma. J Neurooncol 83(1):85–89CrossRef
18.
Liu J, Zheng M, Yang W, Lo SL, Huang J (2018) Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study. J Neurooncol 139(3):609–616CrossRef
19.
Milano MT, Johnson MD, Sul J et al (2010) Primary spinal cord glioma: a Surveillance, Epidemiology, and End Results database study. J Neurooncol 98(1):83–92CrossRef
20.
Fakhreddine MH, Mahajan A, Penas-prado M et al (2013) Treatment, prognostic factors, and outcomes in spinal cord astrocytomas. Neuro-Oncology 15(4):406–412CrossRef
21.
Kaley TJ, Mondesire-Crump I, Gavrilovic IT (2012) Temozolomide or bevacizumab for spinal cord high-grade gliomas. J Neurooncol 109(2):385–389CrossRef
22.
Kheirkhah P, Denyer S, Bhimani AD et al (2018) Magnetic drug targeting: a novel treatment for intramedullary spinal cord tumors. Sci Rep 8(1):11417CrossRef
Metadata
Title
Adult primary high-grade spinal glioma: a nationwide analysis of current trends in treatment and outcomes
Authors
Ravi S. Nunna
Syed Khalid
James S. Ryoo
Ankit I. Mehta
Publication date
01-05-2020
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 3/2020
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-020-03458-z

Other articles of this Issue 3/2020

Journal of Neuro-Oncology 3/2020 Go to the issue

Topic Review

Awake glioma surgery: technical evolution and nuances

Laboratory Investigation

Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma

Laboratory Investigation

RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping

Topic Review

Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology

Laboratory Investigation

High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients

Clinical Study

The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)